DarioHealth (DRIO) announced an agreement with Dexcom (DXCM) to integrate its market-leading CGMs, into Dario’s multi-chronic condition platform. Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health. This agreement enables the integration of data from Dexcom CGMs directly into Dario’s metabolic solution, making it easy for people using the wearable device to benefit from Dario’s highly personalized support. The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DRIO:
- DarioHealth Announces Preliminary Fourth Quarter and Full Year 2022 Operating Results
- DarioHealth sees Q4 revenue $6.7M, consensus $6.03M
- DarioHealth participates in a conference call with Lake Street
- DarioHealth achieves goal of 100 business-to-business contracts in 2022
- DarioHealth announces new partnership with ECES